Antibodi Monoklonal Anti-CD3 Sebagai Terapi Diabetes Mellitus Tipe 1: Sebuah Kajian Sistematis dan Meta-analisis

  • Visakha Vidyadevi Wiguna Mataram University
  • Abiyyu Didar Haq
  • Luh Ade Dita Rahayu
Keywords: Anti-CD3, C-peptide, HbA1C, Insulin, Type 1 Diabetes Mellitus

Abstract

Introduction: Type 1 Diabetes Mellitus (T1DM) is a chronic autoimmune disease which marked by a persistent increase in blood glucose (hyperglycemia). T1DM is thought to be caused by an autoreactivity of T cell which mediates the apoptosis of insulin-producing cells in the pancreas. Those mechanism causes a life-long dependance on exogen insulin. Current immunotherapy strategy is inhibiting or deleting the lymphocyte subset and/or through the use of agents which will induce the tolerance by activating regulatory T cell such as the use of anti-CD3. Therapy using monoclonal antibody also has a continous effect as compared to immunosupressive agents that traditionally being used.
Methods: A systematic review was conducted based on PRISMA through PubMed, ScienceDirect, Directory of Open Access Journal, Wiley, Cochrane Library, Google Scholar, and Scopus, searching for randomized controlled trials which analyze anti-CD3’s effects on clinical outcomes of T1DM patients. Studies selected were then assessed for bias risk with CONSORT criteria. Random-effects meta-analysis was performed to estimate the pooled mean difference (MD) along with their 95% confidence intervals (CIs).
Results: The search yielded ten RCTs with a total of 1,458 subjects. Anti-CD3 intervention is proven to be effective in reducing insulin’s usage (MD -0,18 [95% CI: -0.22, -0.13],I2=59%, p<0,0001) and HbA1C (MD -0.71[95% CI: -1.18, -0.24], I2=78%, p=0.003) significantly. Furthermore, there is another clinical benefits, such as reducing the decrease of C-peptide response significantly.
Conclusion: To conclude, anti CD-3 showed promising results to be widely implemented as treatment for T1DM patients.

References

A. Katsarou, S. Gudbjornsdottir, A. Rawshani, D. Dabelea, E. Bonifacio, B. J. Anderson, L. Jacobsen, D. Schatz and A. Lernmark, "Type 1 diabetes mellitus," Disease Primers, vol. 3, no. 17016, pp. 1-17, 20187.
J. C. Ozougwu, K. C. Obimba, C. D. Belonwu and C. B. Unakalamba, "The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus," academicJournals, vol. 4, no. 4, pp. 46-57, 2013.
L. Lucaccioni and L. Iughetti, "Issues in Diagnosis and Treatment of Type 1 Diabetes Mellitus in Childhood," Journal of Diabetes Mellitus, vol. 6, pp. 175-183, 2016.
B. Saberzadeh-Ardestani, R. Karamzadeh, M. Basiri, E. Hajizadeh-Saffar, A. Farhadi, J. Shapiro, Y. Tahamtani and H. Baharvand, "Type 1 Diabetes Mellitus: Cellular and Molecular Pathophysiology at A Glance," Cell J, vol. 20, no. 3, pp. 294-301, 2018.
A. Iqbal, P. Novodvorsky and S. R. Heller, "Recent Updates on Type 1 Diabetes Mellitus Management for Clinicians," Diabetes & Metabolic Journal, vol. 42, pp. 3-18, 2018.
American Diabetes Association, "Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020," Diabetes Care, vol. 43, no. 1, pp. 598-5110, 2020.
X. Luo, K. Herold and S. Miller, "Immunotherapy of Type 1 Diabetes – Where are We At and," Immunity, vol. 32, no. 4, April 2010.
A. Kaufman and K. Herold, "Anti-CD3 mAbs for treatment of type 1 diabetes," DIABETES/METABOLISM RESEARCH AND REVIEWS, vol. 25, March 2009.
J. Gaglia and S. Kissler, "Anti-CD3 antibody for the prevention of type 1 diabetes - a story of perseverance," Biochemistry, vol. 58, no. 40, October 2019.
K. Herold, W. Hagopian, J. A. Auger, E. Poumian-Ruiz, L. Taylor, D. Donaldson, S. Gitelman, D. M. Harlan, D. Xu, R. A. Zivin and J. A. Bluestone, "Anti CD-3 Monoclonal Antibody in New- Onset Type 1 Diabetes Mellitus," The New England Journal of Medicine, vol. 346, no. 22, 2002.
R. D. Riley, K. G. Moons , K. I. E. Snell, J. Ensor, L. Hooft, D. G. Altman, J. Hayden, G. S. Collins and t. P. A. Debray , "A guide to systematic review and meta-analysis of prognostic factor studies," BMJ, vol. 364, p. k4597, 2019.
J. P. T. Higgins, S. G. Thompson, J. J. Deeks and D. G. Altman, "Measuring inconsistency in meta-analyses," BMJ, vol. 327, p. 557, 2003.
A. Janez, C. Guja , A. Mitrakou, N. Latic , T. Tankova , L. Czupryniak, A. G. Tabak, M. Prazny, E. Martinka and L. S. Duvnjak, "Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review," Diabetes Therapy, vol. 11, no. 11, pp. 387-409, 2020.
L. A. DiMeglio, C. E. Molina and R. A. Oram, "Type 1 diabetes," Lancet, vol. 391, no. 10138, pp. 2449-2462, 2019.
C. K. Cheon, "Understanding of type 1 diabetes mellitus: what we know and where we go," Korean Journal of Pediatrics, vol. 61, no. 10, pp. 307-314, 2018.
K. M. Simmons and A. W. Michels , "Type 1 diabetes: A predictable disease," World Journal of Diabetes, vol. 6, no. 3, pp. 380-390, 2015.
J. Lebastchi, S. Deng, A. H. Lebastchi, I. Beshar, S. Gitelman, S. Willi, P. Gottlieb, E. M. Akirav, A. J. Bluestone and K. C. Herold, "Immune Therapy and B-cell Death in Type 1 Diabetes," Diabetes Journal, vol. 62, pp. 1676-1680, 2013.
K. C. Herold, S. E. Gitelman, M. R. Ehlers, P. A. Gottlieb, C. J. Greenbaum, W. Hagopian, K. D. Boyle, L. Keyes-Elstein, S. Aggarwal, D. Phippard, P. H. Sayre, J. McNamara and J. A. Bluestone, "Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial," Diabetes Journal, vol. 62, pp. 3766-3774, 2013.
W. Hagopian , R. J. Ferry, N. Sherry , D. Carlin, E. Bonvini, S. Johnson, K. E. Stein , S. Koenig, A. G. Daifotis, K. C. Herold and J. Ludvigsson, "Teplizumab Preserves C-Peptide in Recent-Onset Type-1 Diabetes," Diabetes, vol. 62, pp. 3901-3908, 2013.
N. Sherry , W. Hagopian, J. Ludvigsson , S. M. Jain , J. Wahlen, R. Ferry, B. Bode, S. Aronoff, C. Holland , D. Carlin, R. Wilder , K. King, S. Pillemer, E. Bonvini , K. Stein, S. Koenig, K. C. Herold and A. Daifotis , "Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year result from a randomised, placebo-controlled trial," Lancet , vol. 378, no. 11, pp. 487-497, 2013.
K. C. Herold, S. Gitelman, C. Greenbaum, J. Puck, W. Hagopian, P. Gottlieb, P. Sayre, P. Bianchine, E. Wong, V. Seyfert-Margolis, K. Bourcier and J. A. Bluestone, "Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years," Clinical Immunology, vol. 132, no. 2, pp. 166-173, 2009.
S. Demeester, B. Keymeulen, L. Kaufman, A. V. Dalem, E. V. Balti, U. V. d. Velde, Patrick Goubert, K. Verhaeghen, H. M. Davidson, J. Wenzlau, I. Weets, D. Pipeleers and F. Gorus, "Preexisting Insulin Autoantibodies Predict Efficacy of Otelixizumab in Preserveing Residual B-cel Function in Recent-Onset Type 1," Diabetes Care, vol. 38, pp. 644-651, 2015.
S. L. Sherwani, H. A. Khan, A. Ekhzaimy, A. Masood and M. K. Sakharkar , "Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients," Biomarker Insights, vol. 11, pp. 95-104, 2016.
B. Mianowska , W. Fendler , A. Szadkowska, A. Baranowska , E. G. Agaciak , J. Sadon, H. Keenan and W. Mlynarski, "HbA1c levels in schoolchildren with type 1 diabetes are seasonally variable and dependent on weather conditions," Diabetologia, vol. 54, no. 4, pp. 749-756, 2011.
C. Florkowski, "HbA1c as a Diagnostic Test for Diabetes Mellitus – Reviewing the Evidence," The Clinical Biochemist Reviews, vol. 34, no. 2, pp. 75-83, 2013.
K. C. Herold, W. Hagopian, J. A. Auger, E. Poumian-Ruiz, L. Taylor, D. Donaldson, S. E. Gitelman, D. M. Harlan, D. Xu, R. A. Zivin and J. A. Bluestone, "Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus," The New England Journal of Medicine, vol. 346, no. 22, pp. 1692-1698, 2002.
K. C. Herold, S. E. Gitelman, M. Umesh, W. Hagopian, B. Bisikirska, D. Donaldson, K. Rother, B. Diamond, D. M. Harlan and J. A. Bluestone, "A Single Course of Anti-CD3 Monoclonal Antibody hOKT3gamma1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes," Diabetes Journal, vol. 54, pp. 1763-1769, 2005.
K. C. Herold, B. N. Bundy, A. Long, J. A. Bluestone, L. A. DiMeglio and M. J. Dufort, "An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes," The New England Journal of Medicine , vol. 381, pp. 603-613, 2019.
Published
2021-12-18